Investigational Drug Details
| Drug ID: | D010 |
| Drug Name: | Amoxicillin |
| Synonyms: | (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid; Amox; Amoxicillin; Amoxicillin (anhydrous); Amoxicillin anhydrous; Amoxycillin; AX; p-Hydroxyampicillin; α-amino-p-hydroxybenzylpenicillin |
| Type: | Chemical drug |
| DrugBank ID: | DB01060 |
| DrugBank Description: | Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to and , but leads to higher serum concentrations than ampicillin. Amoxicillin was granted FDA approval on 18 January 1974. |
| PubChem ID: | 33613 |
| CasNo: | 26787-78-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C(=O)(O)[C@@H]1N2[C@H](SC1(C)C)[C@@H](C2=O)NC(=O)[C@H](N)c1ccc(cc1)O |
| Structure: |
|
| InChiKey: | LSQZJLSUYDQPKJ-NJBDSQKTSA-N |
| Molecular Weight: | 365.411 |
| DrugBank Targets: | Penicillin binding protein inhibitor |
| DrugBank MoA: | Amoxicillin competitively inhibits penicillin-binding protein 1 and other high molecular weight penicillin binding proteins. Penicillin bind proteins are responsible for glycosyltransferase and transpeptidase reactions that lead to cross-linking of D-alanine and D-aspartic acid in bacterial cell walls. Without the action of penicillin binding proteins, bacteria upregulate autolytic enzymes and are unable to build and repair the cell wall, leading to bacteriocidal action. |
| DrugBank Pharmacology: | Amoxicillin competitively inhibit penicillin binding proteins, leading to upregulation of autolytic enzymes and inhibition of cell wall synthesis. Amoxicillin has a long duration of action as it is usually given twice daily. Amoxicillin has a wide therapeutic range as mild overdoses are not associated with significant toxicity. Patients should be counselled regarding the risk of anaphylaxis, _Clostridium difficile_ infections, and bacterial resistance. |
| DrugBank Indication: | Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of _H. pylori_. |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 completed (NCT01876108) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0116 | NCT01876108 | Phase 2 | Completed | No Results Available | July 2012 | July 8, 2013 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A07432 | 32499918 | Gastroenterol Rep (Oxf) | Effect of Helicobacter pylori-eradication therapy on hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomized-controlled pilot study. | Details |
| A22643 | 24388027 | Mayo Clin Proc | Drug-induced liver injury. | Details |
| A23134 | 24011768 | Med Hypotheses | Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. | Details |
| A35636 | 22798443 | BMJ Case Rep | A hot, swollen joint in a cirrhotic patient. | Details |